OBJECTIVE	The primary study objective was to determine non-inferiority [ lower limit of 95 % confidence interval ( CI ) , -10 % ] in the clinical cure rate achieved with ceftaroline fosamil monotherapy compared with that achieved with vancomycin plus aztreonam in the clinically evaluable ( CE ) and modified intent-to-treat ( MITT ) patient populations .\